Page last updated: 2024-12-07

silicon phthalocyanine pc4

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Silicon phthalocyanine Pc4 is a synthetic organic compound that has gained significant attention for its remarkable photophysical and electronic properties. Its synthesis typically involves a multi-step reaction process, often starting with the condensation of phthalonitrile and a silicon-containing precursor. The resulting molecule exhibits strong absorbance in the visible and near-infrared regions, making it a promising candidate for applications in fields such as dye-sensitized solar cells, organic photovoltaics, and non-linear optics. Extensive research efforts are directed towards understanding the effects of molecular modifications on its optical and electronic properties, with the goal of optimizing its performance in various applications. The unique electronic structure of Pc4, characterized by a delocalized pi-electron system, contributes to its high charge carrier mobility and photostability. These properties make it an attractive material for developing efficient and durable optoelectronic devices.'

Cross-References

ID SourceID
PubMed CID119185
MeSH IDM0351062

Synonyms (14)

Synonym
silicon phthalocyanine
135719-28-7
sipc iv
(oc-6-23)-((3-(dimethylamino)propyl)dimethylsilanolato-o)hydroxy(29h,31h-phthalocyaninato(2-)-n(29),n(30),n(31),n(32))silicon
silicon, ((3-(dimethylamino)propyl)dimethylsilanolato-o)hydroxy(29h,31h-phthalocyaninato(2-)-n(29),n(30),n(31),n(32))-, (oc-6-23)-
hosipcosi(ch3)2(ch2)3n(ch3)2
silicon, ((3-(dimethylamino)propyl)dimethylsilanolato-kappao)hydroxy(29h,31h-phthalocyaninato(2-)-kappan29,kappan30,kappan31,kappan32)-, (oc-6-23)-
nsc 676418
unii-vm2r9z8dtw
silicon phthalocyanine pc4
cl2sipc
DTXSID00159502
3-[dimethyl(oxido)silyl]-n,n-dimethylpropan-1-amine;2,11,20,37,38-pentaza-39,40-diazanidanonacyclo[28.6.1.13,10.112,19.121,28.04,9.013,18.022,27.031,36]tetraconta-1,3,5,7,9,11,13,15,17,19,21(38),22,24,26,28,30(37),31,33,35-nonadecaene;silicon(4+);hydroxid
silicon phthalocyanine 4

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Pc 4-PDT is a safe and tolerable treatment modality that effectively triggers apoptosis in cutaneous neoplasms such as mycosis fungoides."( Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial.
Baron, ED; Colussi, VC; Cooper, KD; Fu, P; Hanneman, KK; Hsia, AH; Malbasa, CL; Miller, JD; Oleinick, NL; Santo-Domingo, D, 2010
)
0.36
"4 mm diameter, 90 μL) containing singlet oxygen at levels toxic to bacteria and fungus."( Bacterial inactivation by a singlet oxygen bubbler: identifying factors controlling the toxicity of (1)O2 bubbles.
Aebisher, D; Bartusik, D; Greer, A; Lyons, AM, 2012
)
0.38

Pharmacokinetics

ExcerptReferenceRelevance
" Before pursuing pharmacokinetic studies, preliminary toxicity studies were undertaken."( Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent.
Callery, PS; Dobson, JM; Egorin, MJ; Eiseman, JL; Sentz, DL; Zuhowski, EG, 1999
)
0.3
" bolus delivery to mice, Pc4 distributed rapidly to all tissues and persisted in most tissues for the duration of each pharmacokinetic study."( Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent.
Callery, PS; Dobson, JM; Egorin, MJ; Eiseman, JL; Sentz, DL; Zuhowski, EG, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (109)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's21 (19.27)18.2507
2000's21 (19.27)29.6817
2010's47 (43.12)24.3611
2020's20 (18.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.11 (24.57)
Research Supply Index4.74 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.88%)5.53%
Reviews2 (1.77%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other110 (97.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]